Cellectis S.A. (NASDAQ:CLLS) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Â Company Participants | --- | --- | --- | |-------|-------|-------------------------------------------| | | | | | | | Arthur Stril - Chief Business Officer | | | | Andre Choulika - Chief Executive Officer | | | | Carrie Brownstein - Chief Medical Officer | | | | Bing Wang - Chief Financial Officer | | | | Conference Call Participants | | | | Gena Wang - Barclays | | | | Yigal Nochomovitz - Citigroup | | | | Kelly Shi - Je ...

EXHIBIT 99.1 Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop lifesaving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company and a majority-owned subsidiary of Cellectis, released today financial results f ...

| --- | --- | --- | --- | --- | |----------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Commitment to a Cure | | | | | | | | | | | | Corporate Presentation March 2022 | | | | | | NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA | | | | | | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2021 Results Earnings Conference Call March 4, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Bing Wang - Chief Financial Officer David Sourdive - Executive Vice President, CMC and Manufacturing Steve Doares - Chief Regulatory and Compliance Officer Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Capital David Windley - Jefferies Raju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

EXHIBIT 99.1 Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track for planned 2022 IND submission for UCART20x22, our first allogeneic dual CAR T-cell product candidate, in B-cell non-Hodgkin's Lymphoma Two manufacturing sites are now fully operational; ...

Cellectis S.A. (NASDAQ:CLLS) Q3 2021 Results Conference Call November 5, 2021 8:00 AM ET Company Participants Andre Choulika - Chief Executive Officer Eric Dutang - Chief Financial Officer Carrie Brownstein - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Kelsey Goodwin - Guggenheim Kelly Shi - Jeffries Hartaj Singh - Oppenheimer & Co Jack Allen - Baird Raju Prasad - William Blair Nick Abbott - Wells Fargo Ingrid Gafanhão - Kempen & Co Operator Greeting ...

Financial Data and Key Metrics Changes - Cellectis reported a cash position of $238 million as of August 6, 2021, down from $244 million at the end of 2020, primarily due to $59 million in net sales proceeds and $46 million in net equity proceeds raised [22][23] - The net loss attributable to shareholders, excluding Calyxt, was $43 million in the first half of 2021, compared to a net income of $3 million in 2020, driven by a decrease in revenues and an increase in R&D expenses [24][25] - The consolidated net loss attributable to shareholders, including Calyxt, was $52 million or $1.17 per share in the first half of 2021, compared to $12 million or $0.29 per share in 2020 [25] Business Line Data and Key Metrics Changes - Cellectis has made significant progress in its clinical trials, including enrolling patients in three Phase 1 dose-escalation trials for UCART22, BALLI-01, and UCARTCS1 [9][10] - The company presented preliminary data for UCARTCS1 at a major conference, validating CS1 as a target for CAR T-cell therapy in multiple myeloma [10] Market Data and Key Metrics Changes - Cellectis has entered into a partnership with Sanofi for the supply of alemtuzumab, which will be used in certain UCART clinical trials, indicating a strategic move to enhance clinical trial support [16] - The company is also focused on expanding its pipeline with new product candidates targeting various cancers, including solid tumors [12][13] Company Strategy and Development Direction - Cellectis aims to leverage its gene editing platform to develop novel proprietary medicines for serious diseases, focusing on hematologic malignancies and solid tumors [27] - The company plans to file INDs for new product candidates in 2022, including UCART20x22 and UCART mesothelin [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering a new phase of development, emphasizing clinical execution and internal product manufacturing capabilities [8][27] - The company is focused on developing its pipeline while maintaining efficient cash management to support operations into early 2023 [22][26] Other Important Information - Cellectis has successfully completed two UCART training runs in its Raleigh GMP manufacturing facility, marking a key milestone in its manufacturing capabilities [18] - The company is preparing to organize a live visit of its manufacturing facility for investors, showcasing its state-of-the-art capabilities [83] Q&A Session Summary Question: Will data for UCART22 be presented at ASH? - Management aims to present data at ASH, with some cohorts expected by the end of the year [31] Question: Thoughts on moving HEAL technology to in-vivo systems? - The focus is currently on ex-vivo systems, with plans to transition to in-vivo once safety and efficacy are established [34] Question: Long-term partnering strategy? - Cellectis remains open to partnerships to accelerate clinical execution, considering past collaborations as beneficial [39][40] Question: Update on UCARTCS1 trial progress? - The trial is progressing well, but specific enrollment numbers are not disclosed due to safety monitoring requirements [70] Question: IP perspective on UCART MK1? - Cellectis believes it has a strong IP position in gene editing, having filed patents long before competitors [60] Question: Solid tumor strategy and first targets? - The first target for solid tumors is likely to be mesothelin CAR-T, focusing on indications like mesothelioma and pancreatic cancer [65]

Cellectis S.A. (NASDAQ:CLLS) Q4 2020 Earnings Conference Call March 5, 2021 8:00 AM ET Company Participants Simon Harnest - Senior Vice President, Corporate Strategy and Finance André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dutang - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC Gena Wang - Barclays Salveen Richter - Goldman Sachs Hartaj Singh - Oppenheimer & Company Yigal Nochomovitz - Citigroup Wangzhi Li - Ladenb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...